Ca_v 1.3-selective inhibitors of voltage-gated L-type Ca²⁺ channels: Fact or (still) fiction?

ABSTRACT: Voltage-gated L-type Ca²⁺ -channels (LTCCs) are the target of Ca²⁺ -channel blockers (CCBs), which are in clinical use for the evidence-based treatment of hypertension and angina. Their cardiovascular effects are largely mediated by the Ca_v 1.2-subtype. However, based on our current understanding of their physiological and pathophysiological roles, Ca_v 1.3 LTCCs also appear as attractive drug targets for the therapy of various diseases, including treatment-resistant hypertension, spasticity after spinal cord injury and neuroprotection in Parkinson's disease. Since CCBs inhibit both Ca_v 1.2 and Ca_v 1.3, Ca_v 1.3-selective inhibitors would be valuable tools to validate the therapeutic potential of Ca_v 1.3

SUBMITTER: Filippini L 

PROVIDER: S-EPMC10953394 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature